Stock listing
NASDAQ:REVB Revelation Biosciences, Inc. Stock
Home listing (NASDAQ) of Revelation Biosciences, Inc.
Follow Revelation Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:REVB
$3.50 USD -0.35 (-9.1%)
Close on Nov 20, 2026
- Day range
- $3.50 – $3.80 USDNov 20, 2026
- Volume
- 9,801 sharesNov 20, 2026
- Market cap
- $2.39M USDAt the close on Nov 20, 2026 · price × 683,442 shares outstanding
- 52-week range
- $3.08 – $40.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $53,652 USDMedian day 6,430 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:REVB · Home | $3.50 USD | -0.35 (-9.1%) | 9,801 | $3.71 | $3.80 | $3.50 | $3.85 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:REVB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.50 | -0.35 | -9.1% | $3.71 | $3.80 | $3.50 | 9,801 | |
| $3.85 | -0.03 | -0.8% | $3.60 | $4.23 | $3.60 | 12,915 | |
| $3.88 | +0.06 | +1.6% | $3.98 | $3.98 | $3.75 | 13,259 | |
| $3.82 | -0.445 | -10.4% | $4.00 | $4.00 | $3.712 | 8,426 | |
| $4.265 | -0.115 | -2.6% | $4.38 | $4.50 | $4.17 | 6,430 | |
| $4.38 | +0.02 | +0.5% | $4.27 | $4.40 | $4.15 | 6,855 | |
| $4.36 | +0.42 | +10.7% | $3.92 | $4.36 | $3.92 | 11,466 | |
| $3.94 | -0.17 | -4.1% | $4.07 | $4.07 | $3.577 | 9,482 | |
| $4.11 | +0.22 | +5.7% | $4.135 | $4.50 | $3.975 | 24,066 | |
| $3.89 | +0.33 | +9.3% | $3.66 | $3.94 | $3.56 | 13,950 | |
| $3.56 | -0.558 | -13.5% | $3.755 | $3.76 | $3.43 | 14,929 | |
| $4.118 | -0.312 | -7.0% | $4.43 | $4.43 | $3.85 | 11,228 | |
| $4.43 | +0.38 | +9.4% | $4.46 | $4.75 | $4.20 | 25,827 | |
| $4.05 | +0.02 | +0.5% | $4.00 | $4.133 | $3.86 | 9,558 | |
| $4.03 | +0.28 | +7.5% | $3.79 | $4.03 | $3.75 | 22,064 | |
| $3.75 | +0.03 | +0.8% | $3.63 | $3.75 | $3.56 | 4,981 | |
| $3.72 | -0.01 | -0.3% | $3.76 | $3.84 | $3.72 | 9,021 | |
| $3.73 | +0.195 | +5.5% | $3.437 | $3.73 | $3.437 | 14,686 | |
| $3.535 | -0.255 | -6.7% | $3.80 | $3.87 | $3.36 | 10,746 | |
| $3.79 | +0.11 | +3.0% | $3.68 | $3.88 | $3.66 | 16,300 | |
| $3.68 | +0.08 | +2.2% | $3.67 | $3.85 | $3.601 | 35,500 | |
| $3.60 | -0.15 | -4.0% | $3.75 | $3.97 | $3.51 | 19,500 | |
| $3.75 | +0.467 | +14.2% | $3.30 | $4.06 | $3.294 | 156,000 | |
| $3.283 | -0.112 | -3.3% | $3.50 | $3.57 | $3.08 | 43,643 | |
| $3.395 | -1.94 | -36.4% | $4.935 | $4.935 | $3.269 | 90,743 | |
| $5.335 | +0.297 | +5.9% | $5.215 | $5.459 | $5.11 | 2,949 | |
| $5.038 | -0.073 | -1.4% | $5.111 | $5.354 | $4.97 | 3,253 | |
| $5.111 | -0.312 | -5.7% | $5.32 | $5.39 | $5.111 | 3,832 | |
| $5.423 | +0.104 | +1.9% | $5.594 | $5.594 | $5.39 | 1,796 | |
| $5.319 | -0.098 | -1.8% | $5.401 | $5.716 | $5.25 | 3,542 | |
| $5.417 | -0.379 | -6.5% | $5.67 | $5.67 | $5.39 | 9,510 | |
| $5.797 | +0.531 | +10.1% | $5.285 | $5.855 | $5.285 | 7,284 | |
| $5.265 | -0.174 | -3.2% | $5.558 | $5.579 | $5.25 | 4,961 | |
| $5.44 | +0.095 | +1.8% | $5.537 | $5.81 | $5.327 | 12,947 | |
| $5.345 | -0.262 | -4.7% | $5.67 | $5.67 | $5.345 | 6,271 | |
| $5.607 | -0.112 | -2.0% | $5.741 | $5.852 | $5.53 | 8,687 | |
| $5.719 | +0.021 | +0.4% | $5.781 | $5.915 | $5.717 | 4,309 | |
| $5.698 | -0.317 | -5.3% | $6.152 | $6.152 | $5.679 | 7,567 | |
| $6.015 | -0.076 | -1.3% | $6.16 | $6.195 | $5.81 | 4,903 | |
| $6.091 | 0.00 | 0.0% | $6.231 | $6.364 | $5.951 | 6,199 | |
| $6.091 | -0.449 | -6.9% | $6.44 | $6.564 | $6.019 | 10,798 | |
| $6.541 | -0.319 | -4.7% | $6.761 | $6.852 | $6.44 | 8,388 | |
| $6.86 | +0.026 | +0.4% | $7.00 | $7.14 | $6.712 | 4,134 | |
| $6.834 | +0.321 | +4.9% | $6.79 | $7.069 | $6.511 | 2,597 | |
| $6.513 | -0.137 | -2.1% | $6.848 | $6.892 | $6.513 | 2,258 | |
| $6.65 | +0.21 | +3.3% | $6.475 | $6.79 | $6.44 | 4,222 | |
| $6.44 | +0.067 | +1.1% | $6.782 | $6.782 | $6.432 | 2,232 | |
| $6.373 | -0.314 | -4.7% | $6.894 | $6.894 | $6.37 | 5,231 | |
| $6.686 | -0.26 | -3.7% | $6.93 | $6.93 | $6.686 | 2,103 | |
| $6.947 | -0.049 | -0.7% | $6.997 | $7.00 | $6.931 | 517 | |
| $6.996 | -0.074 | -1.0% | $7.00 | $7.00 | $6.996 | 703 | |
| $7.07 | 0.00 | 0.0% | $7.14 | $7.14 | $7.036 | 372 | |
| $7.07 | 0.00 | 0.0% | $7.00 | $7.28 | $7.00 | 2,287 | |
| $7.07 | 0.00 | 0.0% | $7.105 | $7.28 | $6.93 | 1,105 | |
| $7.07 | +0.07 | +1.0% | $7.21 | $7.28 | $6.93 | 2,851 | |
| $7.00 | +0.094 | +1.4% | $6.93 | $7.28 | $6.93 | 2,571 | |
| $6.906 | -0.094 | -1.3% | $7.076 | $7.23 | $6.876 | 3,602 | |
| $7.00 | -0.35 | -4.8% | $7.42 | $7.42 | $7.00 | 1,842 | |
| $7.35 | +0.14 | +1.9% | $7.28 | $7.56 | $7.001 | 2,901 | |
| $7.21 | +0.525 | +7.9% | $6.803 | $7.21 | $6.686 | 2,996 | |
| $6.685 | -0.315 | -4.5% | $6.861 | $7.07 | $6.65 | 5,226 | |
| $7.00 | -0.70 | -9.1% | $7.63 | $7.70 | $6.37 | 28,580 | |
| $7.70 | +0.07 | +0.9% | $7.70 | $7.84 | $7.423 | 7,101 | |
| $7.63 | +0.14 | +1.9% | $7.70 | $7.70 | $7.42 | 1,294 | |
| $7.49 | -0.28 | -3.6% | $7.84 | $7.98 | $7.49 | 3,168 |
Splits
6 splits since 2023 · NASDAQ:REVB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-7 | Consolidation | |
| 1-for-4 | Consolidation | |
| 1-for-3 | Consolidation | |
| 1-for-16 | Consolidation | |
| 1-for-30 | Consolidation | |
| 1-for-35 | Consolidation |
- Ticker
- NASDAQ:REVB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 17 slides
Latest news
Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
Nov 16, 2026
Closed $3.82 (-10.4%) on Nov 16, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026
Nov 5, 2026
Closed $3.89 (+9.3%) on Nov 6, 2026
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
Oct 16, 2026
Closed $3.40 (-36.4%) on Oct 16, 2026
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
Aug 19, 2026
Closed $7.77 (0.0%) on Aug 19, 2026
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
Aug 6, 2026
Closed $7.98 (+1.8%) on Aug 7, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
Aug 3, 2026
Closed $7.14 (+7.4%) on Aug 3, 2026
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 21, 2026
Closed $8.05 (0.0%) on Jul 22, 2026
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
Jul 10, 2026
Closed $6.91 (-1.3%) on Jul 13, 2026
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
Jun 1, 2026
Closed $7.63 (-0.5%) on Jun 1, 2026
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
May 11, 2026
Closed $6.85 (+1.9%) on May 11, 2026
Revelation Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 54 in all · newest Nov 16, 2026 · oldest 2021
- Decks
- 18 decks · latest November 2026
Where Revelation Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:REVB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:REVB | BOATS | United States | USD |
Valuation
Price/book 0.3× against a median of 0.5×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$5.92M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.66
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Invion Ltd. · ASX:IVX | US$2.49M | US$3.12M | n/a | 12.2× | n/a | 0.7× | n/a | 0.3× | n/a |
| GRI Bio, Inc. · NASDAQ:GRI | US$2.45M | −US$6.99M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.89 |
| NeuroSense Therapeutics Ltd. · NASDAQ:NRSN | US$2.43M | US$2.20M | n/a | n/a | n/a | n/a | n/a | n/a | 1.41 |
| ValiRx PLC · LSE:VAL | US$2.42M | US$1.15M | n/a | 28.0× | n/a | 0.6× | n/a | 0.0× | n/a |
| BSF Enterprise PLC · LSE:BSFA | US$2.40M | US$2.95M | n/a | 42.7× | n/a | 1.0× | n/a | 0.3× | n/a |
| Mustang Bio, Inc. · NASDAQ:MBIO | US$2.38M | −US$11.89M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.01 |
| Quest PharmaTech Inc. · TSXV:QPT | US$2.36M | US$2.30M | 0.7× | n/a | n/a | 0.1× | n/a | 0.0× | 1.90 |
| HCW Biologics Inc. · NASDAQ:HCWB | US$2.35M | US$8.23M | n/a | 1.2× | n/a | 0.3× | −63.4% | 1.0× | 1.19 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Cynata Therapeutics Limited · ASX:CYP | US$2.26M | US$1.66M | n/a | 1.5× | n/a | n/a | −540.4% | n/a | n/a |
| Median of the others | US$2.39M | US$1.93M | 0.7× | 12.2× | 0.5× | −301.9% | 0.0× | 1.10 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 76.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -33.98 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| James Rolke | Chairman, Director and Chief Executive Officer |
| Chester Zygmont | Chief Financial Officer |
| Carol Odle | Vice President, Clinical Operations |
| Robin Marsden | Senior Vice President, Biology |
Board
| Director | Role |
|---|---|
| James Rolke | Chairman, Director and Chief Executive Officer |
| Jennifer Carver | Director |
| Jess Roper C.P.A. | Director |
| Lakhmir Chawla | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +9.3% |
| Q2 2026 | Aug 6, 2026 · After close | +1.8% |
| Q1 2026 | May 7, 2026 · After close | −5.9% |
| Q4 2025 | Feb 26, 2026 | −6.4% |
| Q3 2025 | Nov 6, 2025 · After close | −2.9% |
| Q2 2025 | Aug 7, 2025 | −4.8% |
| Q1 2025 | May 8, 2025 · After close | +2.7% |
| Q4 2024 | Mar 20, 2025 · Before open | −1.4% |
| Q3 2024 | Nov 8, 2024 · After close | +26.8% |
| Q2 2024 | Aug 9, 2024 · After close | −7.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · After close | −10.7% |
| Q4 2023 | Mar 22, 2024 · After close | +0.8% |
| Q3 2023 | Nov 9, 2023 · After close | −3.9% |
| Q2 2023 | Aug 11, 2023 · After close | −2.5% |
| Q1 2023 | May 22, 2023 · Before open | +7.2% |
| Q4 2022 | Mar 30, 2023 · After close | −3.7% |
| Q3 2022 | Nov 10, 2022 · After close | −1.2% |
| Q2 2022 | Aug 15, 2022 · After close | −5.8% |
| Q1 2022 | May 16, 2022 · Before open | −4.4% |
| Quarter to Sep 30, 2021 | Oct 29, 2021 · After close | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 17 slides | November 2026 |
| Investor Presentation (June 2026) | Investor deck | 19 slides | Jun 1, 2026 |
| Investor Presentation (June 2026) | Investor deck | 23 slides | June 2026 |
| Investor Presentation (February 2026) | Investor deck | 28 slides | Feb 26, 2026 |
| Technical Presentation (September 2025) | Technical | 26 slides | Sep 9, 2025 |
| Investor Presentation (June 2025) | Investor deck | 8 slides | Jun 25, 2025 |
| Investor Presentation (March 2025) | Investor deck | 22 slides | Mar 17, 2025 |
| Investor Presentation (February 2025) | Investor deck | 23 slides | Feb 11, 2025 |
| 29th International Conference on Advances in Critical Care Nephrology: AKI and CRRT 2024 | Conference | 5 slides | Mar 12, 2024 |
| Investor Presentation (January 2024) | Investor deck | 26 slides | Jan 30, 2024 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2023) | Investor deck | 27 slides | Oct 12, 2023 |
| Investor Presentation (May 2023) | Investor deck | 27 slides | May 25, 2023 |
| Investor Presentation (January 2023) | Investor deck | 28 slides | Jan 10, 2023 |
| Investor Presentation (October 2022) | Investor deck | 18 slides | Oct 6, 2022 |
| Investor Presentation (March 2022) | Investor deck | 25 slides | Mar 15, 2022 |
| Investor Presentation (February 2022) | Investor deck | 12 slides | Feb 11, 2022 |
| Investor Presentation (January 2022) | Investor deck | 36 slides | Jan 13, 2022 |
| Petra Acquisition — SPAC Merger (August 2021) | SPAC merger | 39 slides | Aug 31, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock (or common stock equivalents) and warrants Closed: US$4M raised · US$1.1 a share · Warrants at US$1.1 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners (lead) Use of proceeds: Product candidate development incl. Phase 1b study, clinical drug supply, preclinical work, other products, working capital | May 29, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Petra Acquisition Inc., a blank check company (SPAC). Priced at US$10.00 a unit on Oct 7, 2020.
- Price
- US$10.00 a unit
- Units offered
- 7,000,000 units
- Offering size
- US$70 million
- Underwriters' option
- Up to 1,050,000 more units
- Listing
- PAICU on the Nasdaq Capital Market
- Underwriters
- LifeSci Capital LLC, Ladenburg Thalmann, Northland Securities, Inc., Ingalls & Snyder LLC. · In the order on the cover
- Units delivered
- On or about Oct 13, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 14, 2020 |
| Filed publicly | Jul 29, 2020 |
| Amended 4 times | Newest Sep 21, 2020 |
| Shares registered with an exchange | Oct 7, 2020 |
| Declared effective by the SEC | Oct 7, 2020 |
| Final prospectus, with the price | Oct 13, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 13, 2020 |
| CERT · Exchange's certificate of listing | Oct 9, 2020 |
| EFFECT · Notice that a registration is effective | Oct 7, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 7, 2020 |
| S-1/A · Registration statement, amended | Sep 21, 2020 |
| S-1/A · Registration statement, amended | Aug 26, 2020 |
| S-1/A · Registration statement, amended | Aug 19, 2020 |
| S-1/A · Registration statement, amended | Aug 11, 2020 |
| S-1 · Registration statement | Jul 29, 2020 |
| DRS · Draft registration statement | May 14, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 13, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 95.8M | 85.1M | 74.0M | 48.8M | |
| Cost of revenue | 27.1K | 27.9K | 25.0K | 40.0K | 69.2K | 0 | 0 | 0 | ||
| Gross profit | -27.1K | -27.9K | -25.0K | -40.0K | -69.2K | 90.9M | 81.0M | 70.8M | 45.2M | |
| Research and development | 4.06M | 3.55M | 4.15M | 5.38M | 6.91M | 2.56K | ||||
| Selling, general and administrative | 5.01M | 4.43M | 4.51M | 5.49M | 5.04M | 145.5K | 36.3M | 34.0M | 31.3M | 21.5M |
| Operating income | -9.07M | -7.98M | -8.66M | -10.9M | -12.0M | -145.5K | -3.64K | 38.9M | 32.7M | 18.8M |
| Depreciation and amortization | 27.1K | 27.9K | 25.0K | 25.0K | 16.8K | 3.80M | 1.75M | 1.49M | 1.62M | 856.0K |
| EBITDA | -9.04M | -7.95M | -8.63M | -10.8M | -11.9M | 3.65M | 1.74M | 40.4M | 34.3M | 19.6M |
| Interest expense | 35.0K | 41.8K | 0 | 0 | 0 | 0 | 0 | |||
| Income before tax | -8.91M | -15.0M | -120.3K | -10.8M | -12.0M | -1.63M | -3.64K | 37.1M | 29.8M | 14.9M |
| Income tax | 0 | 0 | 0 | 0 | 0 | -3.80K | -171.9K | 9.43M | 13.6M | 6.14M |
| Net income | -8.91M | -15.0M | -120.3K | -10.8M | -12.0M | -1.63M | -3.64K | 27.6M | 16.3M | 8.78M |
| Earnings per share, basic | -23.95 | -1,052.16 | -8.44 | -149.20 | -42.50 | -0.68 | -0.00 | |||
| Earnings per share, diluted | -23.95 | -1,052.16 | -8.44 | -149.20 | -42.50 | -0.68 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 10.7M | 6.50M | 12.0M | 5.25M | 1.27M | 11.7K | 147.1M | 136.4M | 72.2M | 111.5M |
| Short-term investments | 6.49B | 525.3K | 185.7M | 187.6M | 163.2M | 139.6M | ||||
| Receivables | 7.67M | 6.85M | 5.87M | 4.98M | ||||||
| Current assets | 10.8M | 6.57M | 12.1M | 5.41M | 1.91M | 651.3K | 22.7K | 143.3M | 78.1M | |
| Property, plant and equipment | 18.1K | 56.3K | 65.1K | 90.1K | 115.2K | 21.2M | 4.28M | 4.23M | ||
| Goodwill | 26.8M | 26.8M | 26.8M | 26.3M | ||||||
| Total assets | 11.6M | 6.62M | 12.2M | 5.50M | 2.04M | 74.2M | 22.7K | 2.46B | 2.10B | 1.89B |
| Accounts payable | 577.5K | 783.6K | 1.36M | 554.2K | 596.3K | 33.8K | 1.60M | 1.32M | 929.0K | 897.0K |
| Current liabilities | 2.00M | 1.91M | 5.56M | 4.45M | 2.14M | 3.43M | 26.3K | 2.12B | 1.80B | |
| Long-term debt | 174.2M | 94.2M | 108.4M | 116.5M | ||||||
| Total debt | 746.8K | 16.8K | ||||||||
| Total liabilities | 2.72M | 1.91M | 5.56M | 4.45M | 2.14M | 6.34M | 26.3K | 2.19B | 1.91B | 1.73B |
| Shareholders' equity | 8.86M | 4.71M | 6.65M | 1.05M | -99.5K | 3.41M | -3.64K | 264.9M | 188.3M | 168.8M |
| Shares outstanding | 226.3K | 43.5K | 16.5K | 77.4K | 282.0K | 1.82M | 1.82M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.27M | -18.3M | -7.29M | -11.2M | -11.1M | -216.7K | 41.1M | 32.6M | 24.2M | 11.6M |
| Capital spending | 0 | -19.2K | -4 | -4 | -132.0K | -4 | -526.0K | -861.0K | -804.0K | -582.0K |
| Free cash flow | -8.27M | -18.3M | -7.29M | -11.2M | -11.2M | -215.1K | 40.6M | 31.7M | 23.4M | 11.0M |
| Cash from investing | -19.2K | -132.0K | -74.0M | -294.9M | -251.6M | -196.7M | ||||
| Cash from financing | 12.5M | 12.8M | 14.0M | 15.2M | 8.00M | 74.3M | 338.2M | 328.0M | 186.7M | 270.0M |
| Dividends paid | -5.95B | -7.65M | ||||||||
| Share buybacks | 0 | -5.00K | -7.65M | -35.5M | ||||||
| Change in cash | 4.20M | -5.49M | 6.74M | 3.98M | -3.22M | 11.7K | 10.7M | 65.7M | -40.6M | 84.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 13, 2026 | Current report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 19, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jul 13, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 13, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 24, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | May 11, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | May 11, 2026 | Annual report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Apr 15, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 19, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Feb 17, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 12, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Feb 11, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 9, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Feb 6, 2026 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Jan 30, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 28, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 21, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 20, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 3, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 12, 2025 | Offer document | SEC |
| DEF 14A · Proxy statement | Nov 10, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Oct 31, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| 8-K · Current report | Oct 15, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 1, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Sep 30, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Sep 29, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 24, 2025 | Other filings | SEC |
| DEF 14A · Proxy statement | Sep 22, 2025 | Meeting notice | SEC |
| S-3 · Registration statement | Sep 16, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 15, 2025 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Sep 12, 2025 | Meeting notice | SEC |
| 8-K · Current report | Sep 9, 2025 | Current report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 9, 2025 | Current report | SEC |
| 8-K · Current report | Jun 25, 2025 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Jun 9, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 4, 2025 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | May 29, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | May 29, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 29, 2025 | Other filings | SEC |
| 8-K · Current report | May 28, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | May 23, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 23, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 22, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 21, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 20, 2025 | Other filings | SEC |
| S-1 · Registration statement | May 20, 2025 | Offer document | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | Apr 9, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Apr 4, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 17, 2025 | Current report | SEC |
| 8-K · Current report | Mar 6, 2025 | Results | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 11, 2025 | Current report | SEC |
| 8-K · Current report | Jan 30, 2025 | Current report | SEC |
| 8-K · Current report | Jan 21, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jan 13, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jan 7, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 2, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Dec 23, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Dec 20, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 20, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 19, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Dec 19, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 18, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Dec 16, 2024 | Meeting notice | SEC |
| 8-K · Current report | Dec 12, 2024 | Current report | SEC |
| S-3 · Registration statement | Dec 12, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 6, 2024 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Dec 5, 2024 | Meeting notice | SEC |
| 8-K · Current report | Nov 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 21, 2024 | Current report | SEC |
| 8-K · Current report | Sep 27, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Sep 25, 2024 | Other filings | SEC |
| 10-Q/A · Quarterly report, amended | Sep 23, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Sep 23, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Sep 23, 2024 | Annual report | SEC |
| CORRESP · Letter to the SEC | Sep 23, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Sep 13, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 13, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 13, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 10, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 9, 2024 | Other filings | SEC |
| S-3 · Registration statement | Sep 3, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 26, 2024 | Material contract | SEC |
| 8-K · Current report | Aug 19, 2024 | Current report | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 2, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 29, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 23, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 23, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jul 19, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 24, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jun 18, 2024 | Offer document | SEC |
| 8-K · Current report | May 16, 2024 | Meeting outcome | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Apr 15, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 5, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 22, 2024 | Results | SEC |
| 10-K · Annual report | Mar 22, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 8, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Feb 2, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 1, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 30, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Jan 30, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 30, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jan 29, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 23, 2024 | Current report | SEC |
| 8-K · Current report | Jan 22, 2024 | Meeting outcome | SEC |
| SC 13G · Big-stake notice | Jan 3, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Jan 2, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Dec 22, 2023 | Meeting notice | SEC |
| S-1 · Registration statement | Dec 22, 2023 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Dec 12, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 17, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 12, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 2, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 2, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 28, 2023 | Other filings | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| S-8 · Registration statement for employee plans | Aug 11, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2023 | Current report | SEC |
| 8-K · Current report | Jul 14, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jul 7, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jul 7, 2023 | Current report | SEC |
| 8-K · Current report | Jun 29, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 15, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jun 12, 2023 | Current report | SEC |
| 8-K · Current report | May 25, 2023 | Current report | SEC |
| 8-K · Current report | May 22, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 22, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 15, 2023 | Explanation request | SEC |
| DEF 14A · Proxy statement | May 5, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 25, 2023 | Meeting notice | SEC |
This page holds 200 of 390 filings. Open Filings
Cap table
Built by 6ix from Revelation Biosciences, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 683,442
- Fully diluted
- 683,442
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 683,442 | Nov 2, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.10 · expire about May 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 683,442 |
| Oct 16, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anthony C. Hayes Other companies: SIM Acquisition Corp. I (Director · Since at least Mar 7, 2026); Dominari Holdings Inc. (CEO & Chairman of the Board · Since at least Sep 10, 2013); Hoth Therapeutics, Inc. (Director · Feb 14, 2019 – Dec 31, 2019 · Past) | Director · Oct 7, 2020 – Oct 7, 2020 · Past |
| David Dobkin Other companies: LifeSci Acquisition II Corp (Chief Financial Officer, Director · Nov 20, 2020 – Nov 20, 2020 · Past) | Director · Oct 7, 2020 – Oct 7, 2020 · Past |
| James Rolke Other companies: La Jolla Pharmaceutical Co (Chief Scientific Officer · Jan 1, 2017 – May 29, 2020 · Past) | Chairman, Director and Chief Executive Officer · Since at least Jan 10, 2022 |
| Carol Odle | Vice President, Clinical Operations · Since at least Nov 5, 2026 |
| Chester Stanley Zygmont III | Chief Financial Officer · Since at least Apr 30, 2026 |
| Chester Zygmont | Chief Financial Officer · Since at least Aug 18, 2026 |
| Jennifer Carver | Director · Since at least Aug 17, 2026 |
| Jess Roper | Director · Since at least Aug 18, 2026 |
| Kimon Angelides | Director · Oct 7, 2020 – Oct 7, 2020 · Past |
| Lakhmir Chawla | Director · Since at least Sep 27, 2023 |
All 11 people
| Person | Seat |
|---|---|
| Robin Marsden | Senior Vice President, Biology · Since at least Jan 14, 2026 |
Log in to ask 6ix AI your own questions about Revelation Biosciences, Inc.